Schedule 13G
RVPH Schedule 13G filing by UBS
UBS reported beneficial ownership of 746.1K shares, representing 5.82% of REVIVA PHARMACEUTICALS HOLDINGS, INC. in this filing.
FiledMay 7, 2026
Ownership dateMar 31, 2026
Reported shares746.1K
Reported ownership5.82%
Ownership details
Voting and dispositive power reported in the filing
These figures describe the reporting filer’s disclosed voting and investment authority. They should be read together with the reported share count and percentage.
Sole voting power
0
Shared voting power
746.1K
Sole dispositive power
0
Shared dispositive power
746.1K
Price context
Price dates alongside the ownership filing
Price data provides market context around the disclosure. It does not identify the filer’s actual transaction price.
Close near filing date$0.86as of May 7, 2026
Latest tracked price$0.43as of Aug 6, 2026
Source
Original filing and accession
Use the SEC filing as the primary source when you need the complete disclosure, footnotes, exhibits, or reporting-person details.
- Reporting filer
- UBS
- CIK
- CIK0001610520
- Accession
- 0001610520-26-000060
- Form
- Schedule 13G
Read the filing in context